Communiqués Bicycle Therapeutics plc

Actions

BCYC

US0887861088

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 10/07/2026 Varia. 5j. Varia. 1 janv.
4,410 USD +5,50% Graphique intraday de Bicycle Therapeutics plc +1,38% -37,71%

Communiqués

21/05 Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting BU
30/04 Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results BU
21/04 Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting BU
20/04 Bicycle Therapeutics : April 2026 Corporate Presentation PU
20/04 Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026 BU
18/03 Bicycle Therapeutics Announces Oral and Poster Presentations at the AACR Annual Meeting 2026 BU
17/03 Bicycle Therapeutics : March 2026 Corporate Presentation PU
17/03 Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results BU
03/02 Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline BU
12/01 Bicycle Therapeutics : January 2026 Corporate Deck PU
12/01 Bicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026 BU
16/12 Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline BU
12/11 Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference BU
30/10/25 Bicycle Therapeutics : October 2025 Corporate Deck PU
30/10/25 Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results BU
08/09/25 Bicycle Therapeutics Strengthens Board of Directors with New Appointments BU
11/08/25 Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results AQ
08/08/25 Bicycle Therapeutics : August 2025 Corporate Deck PU
08/08/25 Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results BU
02/07/25 Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BU
03/06/25 Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BU
22/05/25 Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual Meeting BU
05/05/25 Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BU
01/05/25 Bicycle Therapeutics : May 2025 Corporate Deck PU
01/05/25 Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results BU
Aucun résultat pour cette recherche